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Abstract
Many long noncoding RNAs (lncRNAs) are deregulated in cancer and contribute to oncogen-
esis. In urothelial carcinoma (UC), several lncRNAs have been reported to be overexpressed
and proposed as biomarkers. As most reports have not been confirmed independently in
large tissue sets, we aimed to validate the diagnostic and prognostic value of lncRNA upregu-
lation in independent cohorts of UC patients. Thus, expression of seven lncRNA candidates
(GAS5, H19, linc-UBC1, MALAT1, ncRAN, TUG1, UCA1) was measured by RT-qPCR in cell
lines and tissues and correlated to clinicopathological parameters including follow-up data
(set 1: N n = 10; T n = 106). Additionally, publicly available TCGA data was investigated for
differential expression in UC tissues (set 2: N n = 19; T n = 252,) and correlation to overall
survival (OS). All proposed candidates tended to be upregulated in tumour tissues, with the
exception of MALAT1, which was rather diminished in cancer tissues of both data sets. How-
ever, strong overexpression was generally limited to individual tumour tissues and statisti-
cally significant overexpression was only observed for UCA1, TUG1, ncRAN and linc-UBC1
in tissue set 2, but for no candidate in set 1. Altered expression of individual lncRNAs was
associated with overall survival, but not consistently between both patient cohorts. Interest-
ingly, lower expression of TUG1 in a subset of UC patients with muscle-invasive tumours
was significantly correlated with worse OS in both cohorts. Further analysis revealed that
tumours with low TUG1 expression are characterized by a basal-squamous-like subtype sig-
nature accounting for the association with poor outcome. In conclusion, our study demon-
strates that overexpression of the candidate lncRNAs is found in many UC cases, but does
not occur consistently and strongly enough to provide reliable diagnostic or prognostic value
as an individual biomarker. Subtype-dependent expression patterns of lncRNAs like TUG1
could become useful to stratify patients by molecular subtype, thus aiding personalized
treatments.
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Introduction
Urothelial carcinoma (UC) represents the most common histological subtype of urinary blad-
der cancer. It is a heterogeneous disease, ranging from low-malignant tumours restricted to
the urothelial tissue layer (stage pTa) to highly malignant and often lethal muscle-invasive car-
cinomas (pT2). Notably, less malignant variants of UC tend to recur quite frequently and
high-grade lower stage tumours may progress to invasive cancers. For these reasons, improved
diagnostic and prognostic biomarkers are desirable, especially to monitor for recurrences, to
identify patients with a poor prognosis and to select appropriate treatments for individual
patients [1].
Long noncoding RNAs (lncRNAs) are a diverse set of transcripts, which are defined as
encompassing more than 200 nucleotides, but do not contain any substantial open reading
frame. Many lncRNAs are expressed in a tissue-specific fashion and have been reported to
undergo expression changes during tumour development or progression [2]. These properties
render them valid candidates as diagnostic or prognostic cancer biomarkers. In addition,
lncRNAs appear to be functionally involved in oncogenesis exerting tumour-promoting or
tumour-suppressive functions [2,3].
Several lncRNAs have been reported to be frequently or consistently overexpressed in UC
and have been proposed as individual diagnostic or prognostic biomarkers; some were more-
over demonstrated to influence proliferation, survival, migration and other cancer-relevant
properties of UC cell lines [4]. These lncRNAs include UCA1 [5], MALAT1 [6], H19 [7], GAS5
[8], TUG1 [9], ncRAN (SNHG16) [10] and linc-UBC1 (BLACAT) [11]. However, only few
lncRNAs have been validated independently for their suitability as biomarkers in different pop-
ulations or for their functional involvement in UC.
For instance, some studies have concurrently reported overexpression of HOXC11-AS, also
known as HOTAIR, in many UCs, which appears to be associated with higher grade and
worse prognosis. In cell culture experiments, HOTAIR likewise often confers a more aggres-
sive phenotype [12,13]. In contrast, the lncRNA MEG3 encoded in an imprinted cluster at
14q32 is strongly down-regulated in most UCs according to two independent reports [14,15].
The requirement for replication studies in this field is further illustrated by the case of the
lncRNA CDKN2B-AS, also known as ANRIL, which was proposed to be upregulated in UC in
one study, but reported as essentially unchanged in another one [16,17]. In addition to differ-
ences in the study populations, this discrepancy may relate to the investigation of different
ANRIL isoforms between the two studies, since a third investigation found frequent upregula-
tion of specific splice variants only [18].
In the present study, we have therefore investigated the expression of the seven candidate
lncRNAs mentioned above, for which insufficient validation data has been published so far.
We used RT-qPCR on total RNA from 12 UC cell lines compared to a benign cell line and a
large tissue set with complete clinical and histopathological data. Where appropriate, we ini-
tially used different primer pairs to check whether transcript variants of the respective lncRNA
differ in their expression across UC cell lines. Expression data from tissues was compared with
results obtained from the TANRIC database [19], which provides convenient access to the
RNA-seq data and clinical information from the comprehensive investigation of UC genomics
by the TCGA consortium. These data were analysed to determine for each lncRNA whether it
was more strongly expressed in cancer tissues than in benign tissues, whether its expression
correlated with important histopathological parameters, and especially whether any associa-
tion with clinical outcome could be discerned.
lncRNA expression in urothelial carcinoma tissues
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Material and methods
Patients and tissues
The set of tissue samples (set 1) used for quantitative real time RT-PCR analysis (RT-
qPCR) consisted of 106 tumour tissues and 10 benign tissues. The majority of the patients
was diagnosed with muscle-invasive and high-grade bladder cancer (13 pTa, 13 pT1, 15
pT2, 44 pT3, 19 pT4; 39 low-grade, 67 high-grade). This tissue set was collected according
to the principles expressed in the Declaration of Helsinki and with written patient infor-
med consent as approved by the ethics committee of the medical faculty of the University
Duisburg-Essen, Study Number 07–3537. A further amendment was approved by the
committee allowing the extensive characterization of such tissues including the analysis of
tissue-RNA by RT-PCR. Median follow up time for the complete cohort was 22.7 months
(range 0.2–198).
Sample preparation and expression analyses were performed and described in accordance
with the MIQE guidelines (minimum information for publication of quantitative real time
PCR experiments) as detailed in the supplementary methods section (S1 File) and supplemen-
tary S1–S3 Tables.
Expression data provided for lncRNAs by the TANRIC database is based on the TCGA
bladder urothelial carcinoma (BLCA) dataset (set 2) consisting of 252 tumour tissue samples
and 19 benign tissue samples, which were with only few exceptions obtained from muscle-
invasive tumours (one pT1, 72 pT2, 118 pT3, 38 pT4, 23 without information about staging).
Median follow-up time for this cohort was 15.9 months (0.49–163).
Analyses of molecular subtype gene expression signatures were performed by means of the
cBioPortal tool based on the provisional TCGA bladder urothelial carcinoma set (“extended”
data set: 413 tumors in total; 408 tumor samples with RNA Sequencing mRNA expression (3
pTa, 121 pT2, 195 pT3 and 59 pT4) and Genesis 1.0 software.
Cell lines
UC cell lines VM-CUB1, SW-1710, HT-1376, 5637, and BFTC-905 were obtained from the
DSMZ (Braunschweig, Germany), the cell lines T-24, RT-4, RT-112, 639-V, J82, UM-UC-3
and UM-UC-6 were kindly made available by Dr. J. Fogh (New York, NY), Dr. M. A. Knowles
(Leeds, UK) and Dr. B. Grossman (Houston, USA) [20]. Cell lines were regularly verified by
DNA fingerprint analysis and checked for mycoplasm contamination. The TERT-immortal-
ized normal human urothelial cell line TERT-NHUC was obtained from Dr. M. A. Knowles
[21] and cultured in keratinocyte serum-free medium (Gibco, life technologies; Carlsbad, CA,
USA) supplemented with 0.25 ng/ml epidermal growth factor, 12.5 μg/ml bovine pituitary
extract and 1:100 ITS (Gibco), 0.35 μg/ml (-)N-epinephrine and 0.33 mg/ml hydrocortisone
(Sigma Aldrich; St. Louis, MO, USA).
RNA extraction and reverse transcription
RNA was extracted using Qiazol reagent (Qiagen; Hilden, Germany) and chloroform and pre-
cipitated by isopropanol. It was further purified by means of the RNeasy Mini Kit (Qiagen)
including on-column DNAse digestion. Quality and integrity of the RNA were assessed on
1.5% agarose gels. Tissue RNA was reverse transcribed using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems; Foster City, CA, USA). RNA from cell lines was
reverse transcribed by means of the Quantitect reverse transcription Kit (Qiagen) according to
the manufacturer.
lncRNA expression in urothelial carcinoma tissues
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Quantitative real time PCR
RT-qPCR analyses in set 1 for the seven lncRNAs and the proliferation marker gene MKI67 as
an additional control were performed on a Roche Lightycler 96 (Roche; Risch, Switzerland).
Reactions were carried out in 20 μl volume using the QuantiTect SYBR Green RT-PCR Kit
(Qiagen) with 10 pmol of each primer. Information on primer sequences, annealing tempera-
tures and standard curves can be obtained from S1 Table. Reactions comprised an initial acti-
vation step for 15 minutes at 95˚C and 40 cycles each with denaturation at 94˚C for 20 s,
annealing at an individual temperature for 20 s and DNA synthesis at 72˚C for 30 s, followed
by a final melting curve analysis. Concentration values are calculated based on standard curves
carried out for each gene and each run using the Roche Lightcycler 96 software (Version 1.1).
PCR efficiency and melting peak integrity was checked for each run. Each sample was assayed
in duplicates. Specific run information on slope, efficiency, coefficient of determination (R^2)
and mean of melting temperature across all samples (Tm) is given in S2 and S3 Tables. TBP
and SDHA were measured as reference genes [22] and a normalization factor was calculated
for each sample using their geometric mean [23]. Expression values of the assessed lncRNAs
and MKI67 are given relative to this normalization factor. See supplementary methods (S1
File) for further information about RT-qPCR conditions according to MIQE guidelines.
Use of the TANRIC and cBioPortal database analysis tools
The TANRIC database provides easy access to publicly available RNA-Seq data for various
tumour entities, especially for lncRNA expression. In the TANRIC database lncRNA expression
was analyzed for the TCGA bladder urothelial carcinoma (BLCA) dataset and queried in the
“My lnRNA”-tool by either lncRNA annotation or, for linc-UBC1 [chr1:205404014–205425214]
and [chr17:74553846–74561430] for ncRAN, in hg19 genomic coordinates. LncRNA expression
values were obtained as log2 RPMK (reads per kilo base per million mapped reads) from the
TANRIC database as indicated in the “My lncRNA”-tool and median expression was calculated
for benign and tumour samples and visualized in boxplots using R. Additional boxplots and
Kaplan-Meier curves for each lncRNA were obtained from the database tool.
The cBioPortal database tools (Oncoprint, download of mRNA Expression z-Scores (RNA
Seq V2 RSEM)) were employed to explore correlations between expression of lncRNA and
marker genes defining molecular subtypes of UC.
Statistical methods
Mann–Whitney U test was performed for paired group comparisons. Overall survival and dis-
ease-specific survival analysis was done using univariate Cox regression analysis. In addition
Kaplan–Meier log-rank test was applied for overall survival. For multivariate analysis, the Cox
proportional hazards regression model was applied and variables with effect on survival in uni-
variate analysis (p 0.05) were included in the Cox proportional hazards regression models.
A p-value of at most 0.05 was considered to be statistically significant. All statistical analyses
were performed with the SPSS software package (version 21; SPSS).
Results
Expression changes of candidate lncRNAs in UC and their correlation
with clinicopathological parameters
Expression of the seven lncRNAs UCA1,MALAT1, H19, GAS5, TUG1, ncRAN (SNHG16) and
linc-UBC1 (BLACAT) was measured by RT-qPCR in UC tissue set 1 consisting of 106 tumor
tissues and 10 benign tissues obtained from radical cystectomies. The results are summarized
lncRNA expression in urothelial carcinoma tissues
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as boxplots depicting relative expression in tumour and benign tissues for each lncRNA (Fig 1,
left). For the same lncRNAs, expression data from the TCGA RNA-sequencing study of 252
UC tissues (set 2) was evaluated via the TANRIC database. Boxplots for comparison between
tumour and benign tissues are likewise presented in Fig 1 (right). For sample set 1 we addition-
ally measured the expression of the proliferation marker gene MKI67 (encoding Ki67). As
expected, MKI67 was weakly expressed in most benign tissues and highly significantly overex-
pressed in the tumour samples (S1 Fig).
The RT-qPCR results on set 1 indicated no difference in the median expression of UCA1
between normal and tumour tissues (Fig 1 left, median 1.19 vs. 1.2). Likewise, only 2/12 inves-
tigated UC cell lines displayed UCA1 overexpression compared to control cells (S2 Fig). In the
TCGA data (set 2, Fig 1 right), a slight (1.5-fold in median expression), but statistically signifi-
cant (p = 0.026) increase in UCA1 expression in tumour tissues was observed (Fig 1). Although
a previous report on suitability of UCA1 as a urine biomarker stated that high expression of
UCA1 is associated with high grade and high stage of UC [3], the TCGA data rather indicates
that increased UCA1 expression originated mainly from higher UCA1 expression levels in
non-muscle invasive UC (NMIBC) compared to muscle-invasive disease (MIBC; S3 Fig right).
Similarly, UCA1 expression tended to be higher in non-invasive and in low-grade tumours
rather than muscle-invasive tumours of set 1 (S3 Fig left), but these differences were not statis-
tically significant (Table 1).
In the univariate analysis patients with high UCA1 expression from tissue set 1 (above
median) had a considerably better overall survival (HR 0.567; 95% CI, 0.367–0.876; p = 0.011;
Table 2), which also remained significant in both multivariate analysis (p = 0.015; Table 3) and
Kaplan-Meier survival curve (Fig 2, left). Concurring results, albeit with lower significance lev-
els, were obtained in both uni-and multivariate analyses of muscle-invasive tumours only (S3
Fig, S4 and S5 Tables). In the TCGA dataset, neither high nor low expression of UCA1was
associated with clinical outcome.
The major isoform of MALAT1 has no intronic sequences, but many different splice vari-
ants are annotated in the ensembl database. Therefore, we first compared results for MALAT1
expression in UC cell lines obtained with primer pairs covering splice variants in the 5’-region
or 3’-region. Expression measured by both primer pairs correlated very well, revealing only
two UC cell lines with high expression compared to benign cells (S2 Fig). Thus, we performed
RT-qPCR analyses for the tissue samples only with the primer pair for the 3’-region, which has
also been applied in reports by Diederichs and colleagues who have studied MALAT1 and
other lncRNAs extensively [24]. The median expression of MALAT1 tended to be lower in can-
cer tissues compared to normal controls in both sample sets, but the differences were not sig-
nificant (Fig 1). However, comparing MALAT1 expression between NMIBC and MIBC
revealed that reduced lncRNA expression in UC originated mainly from muscle-invasive
tumours; this effect was even significant in our own sample set 1 (p = 0.05; Table 1; S3 Fig left).
These findings do not fit with previous reports that MALAT1 expression is increased in UC
and associated with distant metastasis [25,26]. In fact, our uni- and multivariate analyses
revealed a poor prognosis for patients with reduced MALAT1 expression (set 1 univariate
Table 2: HR 0.547, 95% CI, 0.353–0.848, p = 0.007; set 1 multivariate Table 3: HR 0.625, 95%
CI, 0.40–0.976, p = 0.039; TCGA set 2 univariate S6 Table: HR 0.67, 95% CI, 0.558–0.99,
p = 0.044). Kaplan-Meier analysis suggested a shorter overall survival time for patients with
low MALAT1 expression (p = 0.06), especially in the lowest quartile (Fig 2 and S4 Fig).
For the lncRNA H19 no significant expression changes overall were observed in either
patient cohort (Fig 1), although individual NMIBC or MIBC tumour samples showed a clear
upregulation. Similarly, only two of 12 UC cell lines displayed highly increased expression
compared to benign cells (S2 Fig).
lncRNA expression in urothelial carcinoma tissues
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Fig 1. lncRNA expression data for tumour and benign tissues from tissue set 1 and 2. Boxplot
representations of lncRNA expression in set 1 (RT-qPCR, relative expression to geometric mean of reference
genes SDHA and TBP) and set 2 (RNA-Seq in the TCGA bladder cancer cohort, expression as log2 RPMK,
data obtained from the TANRIC database). P-values for difference between control (N) and tumour (T)
samples were calculated by Mann-Whitney U-test.
https://doi.org/10.1371/journal.pone.0176287.g001
lncRNA expression in urothelial carcinoma tissues
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Table 1. Clinical and histopathological parameters of tissue set 1.
Variables UCA1 *100 UBC1 *100 TUG1 *10 ncRAN *100 MALAT1 *10 H19 *10 GAS5 *10
n median
(range)
P median (range) P median
(range)
P median
(range)
P median (range) P median (range) P median
(range)
P
Age
 65 54 1.04 (0.00–
51.55)
0.184 7.58 (0.00–
111.83)
0.937 5.88 (0.19–
19.52)
0.752 5.80 (0.14–
26.16)
0.072 16.53 (0.06–
49.94)
0.300 3.74 (0.03–
68.49)
0.582 1.53 (0.22–
13.27)
0.383
> 65 52 1.43 (0.02–
31.48)
6.07 (0.00–
3361.76)
5.88 (2.67–
34.14)
7.70 (0.55–
23.92)
12.93 (4.14–
45.59)
2.10 (0.06–
166.48)
1.79 (0.05–
10.79)
Gender
Male 76 1.50 (0.00–
31.48)
0.337 7.83 (0.00–
194.30)
0.257 6.06 (2.58–
20.41)
0.326 6.53 (0.55–
26.16)
0.736 13.99 (4.54–
49.94)
0.088 3.59 (0.03–
68.49)
0.068 1.66 (0.22–
10.79)
0.643
Female 30 0.41 (0.01–
51.55)
5.74 (0.00–
3361.76)
5.00 (0.19–
34.14)
5.96 (0.14–
14.77)
11.39 (0.06–
36.73)
0.81 (0.06–
166.48)
1.54 (0.05–
13.27)
Stage
Ta 13 1.57 (0.00–
9.58)
0.801 18.48 (0.00–
194.30)
0.479 6.51 (2.67–
8.90)
0.243 6.39 (0.78–
14.43)
0.186 18.95 (7.03–
49.25)
0.579 7.97 (0.16–
68.49)
0.139 1.75 (0.55–
9.13)
0.545
T1 13 1.15 (0.04–
11.61)
0.902 6.88 (0.84–
101.54)
0.229 7.11 (3.73–
20.41)
0.341 7.07 (3,12–
16.79)
0.059 16.77 (4.14–
38.91)
0.742 0.92 (0.13–
35.62)
0.805 1.86 (0.65–
10.79)
0.113
T2 17 1.25 (0.04–
16.52)
0.949 15.31 (1.22–
180.38)
0.004 5.81 (2.82–
11.25)
0.688 4.38 (1.32–
15.30)
0.104 16.81 (6.97–
33.65)
0.143 1.85 (0.03–
29.44)
0.077 1.65 (0.32–
6.05)
0.652
T3 44 1.57 (0.02–
51.55)
0.077 4.31 (0.00–
111.83)
0.193 5.58 (2.58–
9.20)
0.237 6.35 (0.55–
26.16)
0.611 11.84 (3.37–
45.70)
0.323 4.54 (0.06–
166.48)
0.214 1.44 (0.46–
4.93)
0.309
T4 19 0.28 (0.01–
12.84)
8.45 (0.05–
3361.71)
5.85 (0.19–
34.14)
5.33 (0.14–
23.92)
13.68 (0.06–
49.94)
1.31 (0.10–
58.70)
2.15 (0.05–
13.27)
Non-inv. 26 1.36 (0.00-11-
61)
0.552 9.27 (0.00–
194.30)
0.331 6.58 (2.67–
20.41)
0.419 6.92 (0.78–
16.79)
0.318 17.55 (4.14–
49.25)
0.050 4.33 (0.13–
68.49)
1.000 1.85 (0.55–
10.79)
0.052
Invasive 80 1.19 (0.01–
51.55)
6.33 (0.00–
3361.76)
5.78 (0.19–
34.14)
6.16 (0.14–
26.16)
12.65 (0.06–
49.94)
2.57 (0.03–
166.48)
1.51 (0.05–
13.27)
Grade
G1 7 2.37 (0.01–
9.58)
0.707 9.49 (1.62–
55.40)
0.530 6.84 (2.81–
8.90)
0.680 6.93 (0.78–
15.88)
0.872 16.84 (7.03–
46.59)
0.680 8.41 (0.16–
68.49)
0.484 2.78 (0.68–
3.89)
0.872
G2 32 1.48 (0.00–
11.61)
0.600 14.93 (0.00–
194.30)
0.002 6.35 (2.67–
11.25)
0.098 7.42 (1.32–
23.92)
0.125 14.49 (4.14–
49.25)
0.887 2.21 (0.03–
58.70)
0.708 1.74 (0.32–
9.13)
0.540
G3 67 1.12 (0.01–
51.55)
3.72 (0.00–
3361.76)
5.52 (0.19–
34.14)
5.93 (0.14–
26.16)
13.58 (0.06–
49.94)
2.58 (0.06–
166.48)
1.55 (0.05–
13.27)
Low-grade (G
1–2)
39 1.57 (0.00–
11.61)
0.489 14.55 (0.00–
194.30)
0.001 6.51 (2.67–
11.25)
0.065 7.07 (0.78–
23.92)
0.150 15.04 (4.14–
49.25)
0.736 3.13 (0.03–
68.49)
0.930 1.75 (0.32–
9.13)
0.441
High-grade (G
3)
67 1.12 (0.01–
51.55)
3.72 (0.00–
3361.76)
5.52 (0.19–
34.14)
5.93 (0.14–
26.16)
13.58 (0.06–
49.94)
2.58 (0.06–
166.48)
1.55 (0.05–
13.27)
Lyph node
N0/Nx/M0/Mx 78 1.47 (0.00–
51.55)
0.576 7.66 (0.00–
2261.8)
0.717 5.78 (2.67–
34.14)
0.562 6.64 (0.78–
19.58)
0.552 14.28 (4.14–
49.94)
0.971 2.51 (0.03–
166.44)
0.903 1.57 (0.05–
10.79)
0.333
N + / M+ 28 1.03 (0.01–
16.52)
5.09 (0.00–
111.83)
6.14 (0.19–
10.04)
5.70 (0.14–
26.16)
13.38 (0.06–
45.70)
3.22 (0.06–
58.70)
1.75 (0.33–
13.27)
Smoking
no 29 1.60 (0.01–
51.55)
0.511 6.87 (0.24–
194.30)
0.257 6.56 (0.19–
20.41)
0.214 8.48 (0.14–
23.92)
0.238 12.69 (0.06–
45.70)
0.589 2.35 (0.06–
58.70)
0.292 2.03 (0.46–
13.27)
0.130
yes 58 0.90 (0.00–
31.48)
5.63 (0.00–
111.83)
5.82 (2.58–
9.66)
6.95 (0.78–
26.16)
13.67 (4.14–
49.25)
4.00 (0.08–
166.48)
1.78 (0.05–
9.13)
unknown 19
Control 10 1.19 (0.02–
24.41)
0.716 2.87 (0.13–
6217.9)
0.338 5.36 (3.47–
29.25)
0.836 3.63 (2.29–
31.20)
0.067 16.26 (6.54–
40.11)
0.461 4.94 (0.42–
19.40)
0.473 0.85 (0.71–
12.07)
0.100
Tumor 106 1.20 (0.00–
51.55)
6.67 (0.00–
3361.76)
5.88 (0.19–
34.14)
6.46 (0.14–
26.16)
13.67 (0.06–
49.94)
2.60 (0.03–
166.48)
1.60 (0.05–
13.27)
Information on patient characteristics is given in relation to expression levels of the analysed lncRNAs (median expression relative to the geometric mean of
the reference genes SDHA and TBP, UCA1*100 indicates that the expression values were multiplied with 100 for better interpretation of the data). P-values
were calculated for differences between age groups, gender, non-invasive vs invasive, T stage, low grade vs. high grade, metastatic status, smoking habits
and control vs. tumour. Bold printed p-values are significant (0.05).
https://doi.org/10.1371/journal.pone.0176287.t001
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Likewise, GAS5 expression was not significantly altered in both cohorts (Fig 1). In all UC
cell lines, expression was reduced compared to the normal control (S2 Fig).
A long and a short isoform of ncRAN have been described [10]. Expression analysis by RT-
qPCR in tumour cell lines revealed a strong correlation between both isoforms (S2 Fig). There-
fore, we chose to measure the long isoform in the tissue sets. Concordantly between datasets 1
Table 2. Univariate analyses of the impact of lncRNA expression on patient survival.
Variables Overall survival Disease-specific survival
HR 95% CI P HR 95% CI P
Age
 65 ref. ref.
> 65 1.015 0.659–1.562 0.948 0.929 0.563–1.533 0.774
Sex
Female ref. ref.
Male 0.650 0.410–1.030 0.067 0.655 0.384–1.117 0.121
Stage
Ta-T1 ref. ref.
T2-T3 2.187 1.277–3.742 0.004 5.167 2.219-12-034 <0.001
Grade
G1-G2 ref. ref.
G3 2.458 1.512–3.996 <0.001 4.091 2.125–7.877 <0.001
Lymph node status
pNx / N0 ref. ref.
pN+ 3.551 2.161–5.837 <0.001 5.106 2.952–8.832 <0.001
UCA1 exp. 50%
low ref. ref.
high 0.567 0.367–0.876 0.011 0.657 0.398–1.084 0.100
Linc-UBC1 exp. 50%
low ref. ref.
high 0.953 0.619–1.468 0.828 0.966 0.587–1.592 0.893
TUG1 exp 50%
low ref. ref.
high 0.579 0.375–0.895 0.014 0.588 0.356–0.972 0.038
ncRAN exp. 50%
low ref. ref.
high 0.416 0.543–1.287 0.836 0.605 0.365–1.003 0.052
MALAT1 exp. 50%
low ref. ref.
high 0.547 0.353–0.848 0.007 0.591 0.357–0.78 0.041
H19 exp. 50%
low ref. ref.
high 0.904 0.587–1.390 0.644 0.925 0.562–1.523 0.761
GAS5 exp. 50%
low ref. ref.
high 0.707 0.459–1.091 0.118 0.697 0.423–1.150 0.158
Hazard ratios (HR) with 95% confidence intervals (CI) and p-values (p) were calculated by Cox regression analyses on overall and disease-specific survival
for lncRNA expression levels in set 1. Patients were divided into a low- and a high-expression group for each lncRNA by median expression. Bold printed p-
values were significant (0.05).
https://doi.org/10.1371/journal.pone.0176287.t002
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and 2, median expression of ncRANwas clearly elevated in tumour tissues by approximately
1.7-fold, but the difference was only statistically significant in set 2 (p<0.001, Fig 1). Accord-
ingly, increased ncRAN expression was associated with overall survival of TCGA patients in
univariate analysis (HR 1.53, 95% CI, 1.036–2.249, p = 0.032, S6 Table), but not in multivariate
analysis. However, expression was neither significantly associated with stage, grade nor out-
come in set 1 (Tables 1 and 2, S3 Fig, S4 Table).
Several tumour tissues analysed by RT-qPCR in set 1 clearly overexpressed linc-UBC1, but
overall median expression was only slightly augmented and the difference between tumour
and benign tissues was accordingly not significant (Fig 1). Generally, linc-UBC1 expression
was very low, in four UC cell lines too, expression was below the detection limit (S2 Fig).
Inconsistent with a previous report [11], no significant association was observed with lymph
node metastasis or survival (Table 1, S5 Fig). Instead, linc-UBC1 was much stronger expressed
Table 3. Multivariate analyses of the impact of lncRNA expression on patient survival.
Overall survival Disease-specific survival
Variables HR 95% CI p HR 95% CI p
All cases (Ta-T4)
Stage (T2-T4) 1.329 0.697–2.536 0.388 2.547 0.982–6.603 0.054
Grade (G3) 1.784 1.001–3.178 0.050 2.200 1.052–4.598 0.036
Lymph node metastasis (N+) 2.982 1.748–5.085 <0.001 3.652 2.050–6.504 <0.001
UCA1 (> 50%) 0.573 0.366–0.897 0.015 0.669 0.400–1.121 0.127
Overall survival Disease-specific survival
Variables HR 95% CI p HR 95% CI p
All cases (Ta-T4)
Stage (T2-T4) 1.217 0.646–2.296 0.543 2.412 0.941–6.183 0.067
Grade (G3) 1.734 0.969–3.104 0.064 2.119 1.008–4.456 0.048
Lymph node metastasis (N+) 3.196 1.883–5.427 <0.001 3.865 2.176–6.857 <0.001
TUG1 (> 50%) 0.616 0.392–0.967 0.035 0.656 0.390–1.103 0.112
Overall survival Disease-specific survival
Variables HR 95% CI p HR 95% CI p
All cases (Ta-T4)
Stage (T2-T4) 1.156 0.604–2.211 0.662 2.199 0.843–5.738 0.107
Grade (G3) 2.007 1.126–3.575 0.018 2.264 1.075–4.768 0.032
Lymph node metastasis (N+) 3.017 1.778–5.120 <0.001 3.784 2.129–6.724 <0.001
ncRAN (> 50%) 1.003 0.637–1.580 0.991 0.789 0.466–1.334 0.376
Overall survival Disease-specific survival
Variables HR 95% CI p HR 95% CI p
All cases (Ta-T4)
Stage (T2-T4) 1.073 0.564–2.044 0.830 2.206 0.852–5.713 0.103
Grade (G3) 1.954 1.108–3.448 0.021 2.365 1.141–4.899 0.021
Lymph node metastasis (N+) 2.963 1.748–5.023 <0.001 3.608 2.038–6.388 <0.001
MALAT1 (> 50%) 0.625 0.400–0.976 0.039 0.765 0.459–1.276 0.304
UCA1, TUG1, ncRAN and MALAT1 expression were analysed in multivariate analyses including tumour stage, grade and lymph node metastasis as
parameters. Hazard ratios (HR) with 95% confidence intervals (CI) and p-values (p) are given for overall and disease-specific survival. Bold printed p-values
are significant (0.05).
https://doi.org/10.1371/journal.pone.0176287.t003
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(4-fold in the median) in low grade compared to high grade tumour tissues. In set 2, linc-
UBC1was significantly overexpressed (p<0.001, Fig 1), correlating with worse survival
(p = 0.028, S5 Fig).
While we observed neither significant differential expression of TUG1 in UC cell lines (S2
Fig), nor in sample set 1 (Fig 1 left),nor a significant correlation between TUG1 expression and
either tumour grade or stage (S3 Fig, Tables 1 and 2), TUG1 was significantly increased in the
set 2 TCGA cohort (p = 0.001, Fig 1 right). Intriguingly, TUG1 was the only candidate that
Fig 2. Impact of lncRNA expression levels on patient overall survival in tissue set 1 and 2. Kaplan-Meier curves are shown for
lncRNA candidates displaying significant association with overall survival in set 1 (stratified by median expression; p-values for Cox
regression analysis, time in months). Kaplan-Meier curves for set 2 were obtained from the TANRIC database (time in days).
https://doi.org/10.1371/journal.pone.0176287.g002
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displayed significant results for both data sets in Kaplan-Meier survival analyses (Fig 2). Sur-
prisingly, despite a general tendency towards overexpression, Kaplan-Meier analysis revealed
that in both sample sets a subgroup of patients with low TUG1 expression faced a poor progno-
sis with worse overall survival (Fig 2, set 1 p = 0.012; set 2 p = 0.044). This association between
low TUG1 expression and poor overall survival remained significant for uni- and multivariate
analysis of set 1 (univariate Table 2: HR 0.579, 95% CI, 0.375–0.895, p = 0.014; multivariate
Table 3: HR 0.616, 95% CI, 0.392–0.967, p = 0.035).
Differential expression of lncRNA candidates among molecular subtypes
of UC
To further elucidate the association between low TUG1 expression and poor prognosis in a
subgroup of patients, we investigated an extended set of TCGA tumour samples (provisional
set, n = 408) that also contains a higher number of non-muscle-invasive cases. As illustrated in
Fig 3A, TUG1was again highly expressed in a subset of tumours (n = 166, 40.7%), but 59.3% of
tumour samples (n = 242) displayed low TUG1 expression. As in set 1 (Fig 3B left), in the
extended TCGA dataset more cases with low TUG1 expression were found among the muscle-
invasive tumours (Fig 3B right).
We then investigated whether TUG1 expression might relate to any molecular subtype of
UC. While the discussion about the number of different molecular subtypes in UC and their
according gene signatures is ongoing, a consensus has been reached on the existence of basal-
squamous-like subtype (BASQ) [27], which is consistently associated with poor prognosis
across all studies. According to the consensus its minimal subset of expression markers
includes increased expression of cytokeratins (KRT) 5, 6 and 14 and reduced expression of
FOXA1 and GATA3. Indeed, in the extended TCGA data set most tumours with low TUG1
could be assigned to the BASQ type with significant upregulated KRT5 and KRT14 expression
and significantly lower expression of luminal markers FOXA1 and GATA3 (Fig 3C and 3D, Fig
4A). On the contrary, tumours with significantly increased TUG1 expression, which encom-
pass 8% of TCGA cases, were usually positive for markers of a luminal subtype, e.g. FOXA1,
GATA3, but not for basal KRTs (Fig 3C). Notably, about one third of cases with variable TUG1
expression could not be straightforwardly assigned to a molecular subtype (intermediate
pattern).
To substantiate the association of low TUG1 expression with the BASQ subtype, we
included further marker genes reported to define molecular subtypes of UC. Since no defini-
tive consensus signatures for the other molecular subtypes have been agreed on, we applied a
marker signature published in a recent meta-analysis by Dadhania et al [28]. Hierarchical clus-
tering analysis of the extended TCGA data set for a panel of 30 coding genes distinguishing
between subtypes and the lncRNA candidates demonstrated again an association between low
TUG1 expression and the basal-like subtype (Fig 4A). Similar expression patterns across these
tumour samples became evident for UCA1 and MALAT1 (Fig 4A), suggesting that patients
with low expression of these lncRNAs might also belong to the BASQ subtype.
A recent large-scale study on NMIBC by Hedegaard and colleagues reported that NMIBC
can be subgrouped into at least three molecular subclasses [29]. This study compared tumour
samples among each other and not differential expression compared to benign tissues, which
are not usually available from these patients. Therefore, we could not simply use this data to
confirm our results on differential expression between NMIBC, MIBC and benign tissues.
However, some of our lncRNA biomarker candidates were also found to be differentially
expressed among subclasses of NMIBC. GAS5, H19 and ncRAN displayed the highest expres-
sion levels in differentiated class 1 tumours, MALAT1 and TUG1were rather highly expressed
lncRNA expression in urothelial carcinoma tissues
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in basal-like class 3 tumours (Fig 4B, see S3 Table in Ref. 29). Taken together, these data sug-
gest that lncRNA expression may not only vary between NMIBC vs MIBC, but even between
their respective molecular subtypes.
Discussion
The major aim of this study was to validate the diagnostic and prognostic value of lncRNAs
that were postulated in original publications and reviews as individual biomarkers for urothe-
lial carcinoma [4,5,6,7,8,9,10,11,30]. With the exception of GAS5, all other candidates were
reported to be significantly upregulated.
While urinary markers are evidently clinically useful, our study focused on tumour tissues
based on the postulates that a robust and clinically applicable RNA biomarker for the identifi-
cation of UC should be strongly and regularly overexpressed across large and independent
cohorts of patients with UC and that its degree of overexpression should correlate with histo-
pathological parameters indicating worse prognosis or independently predict prognosis. To
this end, we analysed two distinct lncRNA expression datasets from different populations and
obtained by different assays. Our own tissues sample set investigated by RT-qPCR came from
an urban population in an industrial region of Germany (set 1), whereas the TCGA dataset
(set 2) was assembled from US-American patients using next generation RNA-sequencing.
Briefly, our analysis of public TCGA data for seven lncRNA candidates by means of the TAN-
RIC database tool identified four of them to be significantly higher expressed in tumour tissues
compared to control tissues, but for all but one the differences were slight, with medians differ-
ing by a factor less than 2-fold. In set 1, the direction of the expression changes between
tumour and benign tissues concurred for all seven candidates with the TCGA data, but none
of the candidate lncRNAs showed significant overexpression in tumours or reproducible
strong prognostic value. Strikingly, for two candidates we obtained results from both datasets
that were opposed to previous reports. MALAT1 was reported to be overexpressed in UC [6],
whereas we observed reduced expression in both sets. Conversely, GAS5 was expected to be
downregulated in UC [8], but was rather upregulated in both our cohorts.
There are many potential confounders that might account for the differences between the
present study and previous reports, including technical issues like the cellularity of samples,
quality of RNA and of the assays used as well as differences relating to patient populations. A
closer analysis, as detailed below for the individual lncRNAs, suggests however that the most
important factors relate to the biological heterogeneity of UC. Specifically, it is well known
that non muscle-invasive tumours (NMIBC) differ substantially from muscle-invasive
tumours (MIBC) with regard to tumour biology and molecular alterations. Thus, divergent
results from different studies might originate from the varying abundance of tumour stages
across the investigated cohorts. Most previous reports have investigated mixed cohorts of
NMIBC and MIBC, whereas especially the TCGA cohort is heavily biased towards MIBC.
However, expression differed significantly between NMIBC and MIBC only for UCA1 and
Fig 3. Correlation between low TUG1 expression in UC and Basal-Squamous-like subtype. (a) Waterfall plot representing TUG1 expression
in tumour samples of the extended TCGA tumor tissue set (n = 408). TUG1 expression is given as z-scores. The reference for calculating z-scores
of RSEM data in TCGA studies are diploid samples. Samples with high expression had a z-score above 0, specimen with low expression had
negative values. (b) Boxplot representations comparing TUG1 expression in muscle-invasive and non muscle-invasive tumours of set 1 and
extended set 2. (c) Heat map clustering for KRT5, KRT6, KRT14, FOXA1 and GATA3 with TUG1 expression in the TCGA cohort (expression levels
are given as a colour gradient between dark blue (low expression) and red (high expression)). The tumour cluster with low TUG1 expression is
shown in the left panel, that with a high expression in the centre panel and tumours with an intermediate expression pattern cluster in the right panel.
(d) Expression levels of KRT5, KRT14, FOXA1 and GATA3 in tumours from the TCGA cohort with a TUG1 expression above median (TUG1 high)
and below median (TUG1 low). P-values for difference between high and low TUG1 expressing group were calculated by Mann-Whitney U-test
(*p0.05, ***p0.001).
https://doi.org/10.1371/journal.pone.0176287.g003
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MALAT1 and only in either set 1 or set 2. More prominently, our own results for MIBC along
with a recent comprehensive transcriptome analysis of NMIBC by Hedegaard et al. [29] sug-
gest a high degree of heterogeneity in the expression of lncRNAs between molecular subtypes
of UC. Specifically, these authors reported that GAS5, H19 and ncRANwere more strongly
expressed in class 1 NMIBC, representing a more differentiated subtype with a lower risk for
progression, whereas MALAT1 and TUG1 were more strongly expressed in the newly defined
basal-like class 3 NMIBC [29]. Notably, in accord with this idea, lncRNAs have been shown to
often exhibit strong cell-type and tissue-specific patterns of expression [2]. Therefore, it could
be rather difficult to identify a single lncRNA biomarker that robustly distinguishes all stages
and subtypes of UC in the same fashion as certain lncRNAs like PCA3 are able to identify
almost all prostate cancer cases [31]. Rather, lncRNAs like TUG1might turn out to be most
valuable as biomarkers as part of a panel to cover UC subtypes for diagnosis.
The best studied lncRNA candidate to date is arguably UCA1which has been described as a
potential urinary biomarker for UC by several groups. Notably, most of these studies have
investigated urine sediments [32] rather than tissue samples, applying RT-qPCR [5] or semi-
quantitative RT-PCR [33,34]. UCA1was originally reported to be largely restricted to embry-
onic tissues and cancers and not to be expressed in normal bladder tissue [34], but it is clearly
detectable by sensitive techniques in benign bladder tissues. In UC tumour tissues, we found a
moderate increase of UCA1 expression, which in the TCGA set (set 2) resulted mainly from
high expression levels in papillary tumours. Concurringly, a follow-up study on UCA1 as a uri-
nary biomarker found UCA1 urine analysis to be particularly efficient for detection of pT1
tumours [33]. Conceivably, increased detection of UCA1 in urinary sediments might reflect
only partly increased expression in cancer tissues, but instead increased shedding of urothelial
cells into urine in tumour patients. Analogously, Cytokeratin 20 mRNA, a marker of differenti-
ated urothelial cells expressed in many urothelial carcinomas, is increased in urinary sediments
of UC patients [35].
As for UCA1, we observed overexpression of linc-UBC1 in many UC, but significant
increases only in the TCGA dataset. This finding fits reasonably with a previous report,
whereby linc-UBC1 was upregulated in 60% of 102 bladder cancer tissues by more than
1.5-fold [11]. Notably, linc-UBC1 expression was very low in many tissues. Concordant with
the previous report, high linc-UBC1 expression was associated with worse survival in the
TCGA cohort, but neither associated with survival nor lymph node status in the samples ana-
lysed by RT-qPCR. However, expression near the detection limit in many cancer tissues would
limit assay sensitivity and thus suitability of linc-UBC1 as a biomarker.
Unexpectedly, in view of previous reports on MALAT1 overexpression in UC [2, 26],
MALAT1 expression was rather diminished in UC cell lines and tumour tissues compared to
normal tissues in our cohorts. This discrepancy may relate to significant differences in
MALAT1 expression between NMIBC and MIBC. In our sample set 1 MALAT1 expression
was diminished in invasive tumours compared to benign tissues, whereas NMIBC displayed
rather upregulation. Low MALAT1 expression in MIBC, moreover, appears to be associated
with the BASQ subtype, as revealed by hierarchical clustering analysis (Fig 4). The association
of low MALAT1 expression with poor survival may therefore reflect its association with the
Fig 4. Association of differential lncRNA expression with molecular subtypes of UC. (a) TCGA expression data (z-scores) of the
extended dataset (n = 408) was downloaded for genes defining molecular subtypes of MIBC according to Dadhania et al [28] and
samples were assigned to the indicated subtypes by hierarchical clustering analysis using Genesis 1.0. Expression data of lncRNA
candidates was downloaded accordingly, data was not available for linc-UBC1 and ncRAN. (b) Illustration of differential expression
(log2 fold change) of lncRNA candidates between molecular subclasses of NMIBC based on data published by Hedegaard et al (see
reference for S3 Table) [29].
https://doi.org/10.1371/journal.pone.0176287.g004
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more clinically aggressive basal-like subtype. This contention is partly compatible with other
reports in the literature. In a study by Fan et al. [25] 62 of 95 investigated bladder cancers were
NMIBC and MALAT1 was rather upregulated. In the large-scale transcriptome analysis of
early-stage UC by Hedegaard et al [29] MALAT1 was likewise expressed most prominently in
one NMIBC subgroup, basal-like class 3. Thus, opposite to the results for muscle-invasive UC
where low MALAT1 expression was associated with basal-like characteristics, in NMIBC
MALAT1 upregulation correlated with basal-like characteristics, but not necessarily with dis-
ease progression. Additional published studies on MALAT1 in UC are difficult to compare as
only small sample numbers were investigated and information on histopathological character-
istics is not comprehensive [26]. Two meta-analyses of 10 studies on MALAT1 in various can-
cer types indicated a relatively consistent association of increased MALAT1 expression with
survival in various types of cancer, but some studies analysed only few cases [36, 37]. Clearly,
further studies on MALAT1 should be conducted to ascertain the association of its expression
with tumour subtypes. Moreover, given the assumption that lncRNAs commonly act in a con-
text-dependent fashion, the function of MALAT1 should be investigated in different UC
molecular subtypes.
H19 expression was not significantly altered between tumour and benign tissues of both
sample sets and no association with tumour stage or other clinical parameters was found.
Notably, H19 expression varied across a broad range. H19 is one of the first discovered long
noncoding RNAs and its gene is imprinted. Altered expression could therefore be due to epi-
genetic as well as genetic changes of the imprinted gene cluster at 11p15.5. Previously, Luo
et al. reported a strong increase in H19 expression in 24 bladder tumour specimens over adja-
cent normal tissue [8], but strangely, expression measured by RT-qPCR ranged across 15
orders of magnitude. More recently, Li et al. [38] reported more moderate increases in 40
tumours (mostly NMIBC) vs. 19 benign tissues and an excellent association with grading.
Hedegaard et al observed significant expression changes in their large NMIBC cohort and
found H19 the highest expressed lncRNA in well-differentiated class 1 tumours with a low risk
for progression [29]. In an older report, H19 mRNA expression in bladder cancer was studied
by in situ hybridization on paraffin sections [39]. Thus, again, varying tumour population and
detection techniques might account for the differences among the findings.
For GAS5, we observed neither significant differential expression between tumour and
benign tissues nor associations of expression with histopathological parameters or prognosis.
However, expression was increased in many NMIBC tumours compared with benign tissues.
Accordingly, Hedegaard et al [29] observed significantly increased GAS5 expression in class 1
NMIBC tumours. Previously, GAS5 had been reported to be downregulated based on a cohort
of 12 NMIBC and 16 MIBC [8], but the differences between these subtypes were not detailed.
Based on these results and experiments in one bladder cancer cell line, a tumour suppressive
function was postulated [40], which would not fit well with the newer results in tissues.
For ncRAN, deregulation has been reported in neuroblastoma [41], colorectal cancer [42]
and in bladder cancer, where a limited number of cancer tissues were investigated by semi-
quantitative PCR [10]. Experimental overexpression of ncRAN enhanced cell proliferation,
migration and invasion in the well-differentiated UC cell line RT-4. Accordingly, ncRAN
tended to be overexpressed, albeit moderately, in the cancer tissues in our study, but the associ-
ation of lower expression with worse prognosis in one sample set argues against an important
function of ncRAN upregulation in tumour progression. In addition, Hedegaard et al reported
increased ncRAN expression in differentiated and good prognosis class 1 tumours likewise
arguing against a decisive function in tumour progression [29].
Upregulation of TUG1 and an association with higher tumour stages in UC was reported in
previous studies. In the first study, TUG1was elevated by 1.74-fold in the mean in 44 cancer
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tissues compared to adjacent normal tissues [9]. Another study detected TUG1 transcripts in
54 bladder cancer tissues by RT-qPCR; expression in normal tissues was not investigated [43].
A third study observed significant overexpression in 47 muscle-invasive tumours compared to
paired benign tissues, an association with metastasis and shorter overall survival [44]. We
found modest, but not consistently statistically significant increases of TUG1 in cancer tissues
across both tissue sets. Strikingly, TUG1was the only investigated lncRNA candidate that was
significantly associated with survival in Kaplan-Meier analyses across both cohorts, but unex-
pectedly, low rather than high TUG1 expression was significantly correlated with poor overall
survival, which remained significant in multivariate analysis. Interestingly, Zhang et al. like-
wise found diminished TUG1 expression in non-small cell lung carcinoma (NSCLC) to be
associated with higher tumour stage and size as well as significant poorer overall survival in
uni- and multivariate analyses [45]. In their study, TUG1 knockdown in NSCLC cell lines pro-
moted cellular proliferation, whereas in T24 bladder cancer cells TUG1 overexpression
increased cell invasion [9, 44].
A new finding in our study was the association of low TUG1 expression with a particular
molecular subtype of muscle-invasive UC, the basal subtype with squamous differentiation
patterns (BASQ). While the definition of molecular subtypes in UC is still somewhat contro-
versial, a consensus has been reached on the existence of this particular subtype among MIBC,
its association with poor prognosis and a minimal set of defining markers [27]. Among five
markers for BASQ, low TUG1 expression significantly correlated with four, i.e. high expression
of Cytokeratins 5 and 14 and low expression of FOXA1 and GATA3. The correlation of low
TUG1 expression with poor prognosis might therefore reflect its relation to the BASQ molecu-
lar subtype with its known worse clinical behaviour. As discussed above, low expression of
MALAT1 and UCA1might similarly be related to the BASQ subtype.
Taken together, these observations hint at cancer subtype-specific expression and context-
dependent functions of TUG1which should be considered in future studies. Of note, Zhang
et al. proposed TUG1 as a direct transcriptional target of p53 and reported that TUG1 was not
induced in cell lines depleted of p53 or harbouring common p53 mutations [45]. P53 muta-
tions are common in urothelial carcinomas, especially in the BASQ subtype, and might explain
low TUG1 expression in some tumour tissues.
In conclusion, we observed that few of the previously reported changes in lncRNA expres-
sion or their association to histopathological parameters and patient prognosis could be
robustly confirmed across two further large independent patient cohorts. In particular, overex-
pression of lncRNAs was often restricted to a subset of the cases or was moderate in extent. In
addition to technical issues, varying proportions of tumour stages and molecular subtypes are
likely to account for the differences between studies. Notably, both our sample set and the
TCGA cohort consist predominantly of muscle-invasive tumours and our data are not repre-
sentative for NMIBC. Moreover, the case of UCA1 demonstrates that tissue and urinary bio-
markers might differ. Taken together, our study clearly demonstrates that the identification of
reliable lncRNA biomarkers for urothelial carcinoma demands validation studies in indepen-
dent patient cohorts with large sample numbers which take tumour stages and molecular sub-
types into account. In addition, lncRNAs might deserve investigation as components of
biomarker panels for UC subtypes.
Supporting information
S1 Fig. Quality controls for tissues of set 1. (a) To further characterize the quality/ purity of
tissue samples from set 1 expression of the proliferation marker Ki67 (gene: MKI67) was deter-
mined in all samples by RT-qPCR. RNA expression illustrated as boxplot representation
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(relative expression to geometric mean of reference genes SDHA and TBP). P-values for differ-
ence between benign (Normal) and tumour samples (Tumour) were calculated by Mann-
Whitney U-test. (b) Two representative H&E stainings of tumour tissue sections used to evalu-
ate histology, quality and cellularity of the sample are given.
(TIF)
S2 Fig. lncRNA expression in UC cell lines. Relative expression of the seven lncRNA candi-
dates across 12 UC cell lines and a benign control cell line (TERT-NHUC) is illustrated in bar
graphs. Cell lines were classified into non-basal like and basal-like according to Earl et al [20].
Two different primer assays detecting various numbers of transcript variants had been evalu-
ated for MALAT1 and ncRAN across the cell lines.
(TIF)
S3 Fig. lncRNA expression data of set 1 and 2 analysed separately for NMIBC and MIBC.
Boxplot representations of lncRNA expression in set 1 (left, RT-qPCR, relative expression to
geometric mean of reference genes SDHA and TBP) and set 2 (right, RNA-Seq in the TCGA
bladder cancer cohort, expression as log2 RPMK, data obtained from the TANRIC database).
P-values for difference between control (N) samples, non-muscle invasive stages (pTa/pT1,
NMIBC) and muscle-invasive tumours (T2-T4, MIBC) were calculated by Mann-Whitney U-
test.
(TIF)
S4 Fig. Kaplan Meier Analysis for overall survival of patients of set 1 divided in subgroups
based on lncRNA expression. Kaplan Meier analysis for quartiles of lncRNA expression in set
1 as indicated and overall survival (stratified by three cutpoints, time in months).
(TIF)
S5 Fig. Impact of lncRNA expression levels on patient overall survival in tissue set 1 and 2.
Kaplan-Meier curves are shown for each lncRNA stratified by median expression. Kaplan-
Meier curves for set 2 were obtained from the TANRIC-database. Only data for lncRNAs
which did not show a significant difference for set 1 are shown (p-values for Cox regression
analysis).
(TIF)
S6 Fig. Analysis of RT minus controls. RT minus controls without reverse transcriptase were
included in the analysis of assays using primers that were not exon spanning to exclude that
results were affected by contamination with genomic DNA. Raw quantified values are given
(related to the internal standard curve for the respective gene). Without RT fluorescence sig-
nals remained below the detection limit (n.d.).
(TIF)
S1 Table. Primer sequences and PCR conditions. Primer sequences used in RT-qPCR analy-
ses in 5’->3’ orientation and further information regarding PCR assay design, reaction condi-
tions and the reference bladder or prostate cancer cell line used for standard curve (Ref. std.
curve) are given.
(PDF)
S2 Table. Information on RT-qPCR run performance. For each lncRNA three RT-qPCR
runs were conducted with normal and tumor samples distributed equally. Information on
slope of the standard curve, resulting efficiency, R^2, melting temperature Tm, the Y-Intercept
and Cq values of negative controls (Cq neg. “-”equivalent to undetectable) are given for each
run. According to the melting curve analysis the Cq result for the negative control did not
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result from a contamination by the specific amplicon.
(PDF)
S3 Table. Information on RT-qPCR run performance (2nd). For the second reverse tran-
scription of tissue sample RNA RT-qPCR runs were conducted with normal and tumor sam-
ples distributed equally. Information on slope of the standard curve, resulting efficiency, R^2,
melting temperature Tm, the Y-Intercept and Cq values of negative controls (Cq neg. “-”equiv-
alent to undetectable) are given for each run. According to the melting curve analysis the Cq
result for the negative control did not result from a contamination by the specific amplicon.
(PDF)
S4 Table. Univariate analyses of the impact of lncRNA expression on survival of patients
with MIBC. Hazard Ratios (HR) with a 95% Confidence Interval (CI) and p-values (P) were
calculated by Cox regression analyses on overall and disease-specific survival for lncRNA
expression levels for all patients with T2-T4 tumors in set 1. Patients were divided into a low-
and a high-expression group for each lncRNA by median expression. The cut-off is based on
the whole Ta-T4 cohort. Bold printed p-values were significant (0.05).
(PDF)
S5 Table. Multivariate analyses of the impact of lncRNA expression on survival of patients
with MIBC. UCA1, TUG1, ncRAN and MALAT1 expression had a statistically significant
impact on patient overall or disease-specific survival and were further analysed in the multi-
variate analyses including tumor stage, grade and lymph node metastasis as parameters. Haz-
ard Ratios (HR) with a 95% Confidence Interval (CI) and p-values (p) are given for overall and
disease-specific survival. Bold printed p-values were significant (0.05).
(PDF)
S6 Table. Univariate analyses of the impact of lncRNA expression on patient survival
(TCGA). Hazard Ratios (HR) with a 95% Confidence Interval (CI) and p-values (P) were cal-
culated by Cox regression analyses on overall and disease-specific survival for lncRNA expres-
sion levels in set 1. Patients were divided into a low- and a high-expression group for each
lncRNA by median expression. Bold printed p-values were significant (0.05).
(PDF)
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(PDF)
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